Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study) An open-label, uncontrolled pilot trial has shown that JAK sign
Tweet Content
Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study)
An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with PMR.
https://t.co/sJcq9lMP1l https://t.co/zvmPs3SdCw
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off